KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Medical - Instruments & Supplies
Market Cap$1.26B
5Y Perf.-13.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KMTS vs EW
Revenue, margins, valuation, and 5-year total return — side by side.
EW
Edwards Lifesciences Corporation
Medical - Devices
Market Cap$47.72B
5Y Perf.+14.2%
KMTS vs EW — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KMTS | EW |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $1.26B | $47.72B |
| Revenue (TTM) | $84M | $6.07B |
| Net Income (TTM) | $-145M | $1.07B |
| Gross Margin | 48.8% | 78.1% |
| Operating Margin | -171.5% | 26.7% |
| Forward P/E | — | 27.5x |
| Total Debt | $44M | $705M |
| Cash & Equiv. | $238M | $2.94B |
KMTS vs EW — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KMTS
EW
| Stock | Mar 25 | May 26 | Return |
|---|---|---|---|
| KESTRA MEDICAL TECH… (KMTS) | 100 | 86.4 | -13.6% |
| Edwards Lifescience… (EW) | 100 | 114.2 | +14.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KMTS vs EW
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EW leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. KESTRA MEDICAL TECHNOLOGIES, LTD. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
The Growth Play
KMTS is the clearest fit if your priority is growth exposure.
- Rev growth 115.1%, EPS growth -151.5%
- 115.1% revenue growth vs EW's 11.5%
- 0.2% yield; 5-year raise streak; the other pay no meaningful dividend
Best for: growth exposure
EW
Edwards Lifesciences Corporation
The Income Pick
EW carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.65
- 133.4% 10Y total return vs KMTS's -1.5%
- Lower volatility, beta 0.65, Low D/E 6.8%, current ratio 3.72x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KMTS | 115.1% revenue growth vs EW's 11.5% |
| Quality / Margins | EW | 17.6% margin vs KMTS's -173.0% |
| Stability / Safety | EW | Beta 0.65 vs KMTS's 1.87, lower leverage |
| Dividends | KMTS | 0.2% yield; 5-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | EW | +10.3% vs KMTS's -1.5% |
| Efficiency (ROA) | EW | 8.0% ROA vs KMTS's -48.8%, ROIC 15.5% vs -6.6% |
KMTS vs EW — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
KMTS vs EW — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEWLAGGINGKMTS
KMTSKESTRA MEDICAL TECHNO…
0leads
EWEdwards Lifesciences …
4leads
6 Total Categories
CATEGORYLEADERvs KMTSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EW4/6
Valuation MetricsMultiples, price ratios, and targets
EW2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
EW6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
EW2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
EW leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EW is the larger business by revenue, generating $6.1B annually — 72.5x KMTS's $84M. EW is the more profitable business, keeping 17.6% of every revenue dollar as net income compared to KMTS's -173.0%. On growth, KMTS holds the edge at +62.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KMTSKESTRA MEDICAL TE… | EWEdwards Lifescien… |
|---|---|---|
| RevenueTrailing 12 months | $84M | $6.1B |
| EBITDAEarnings before interest/tax | -$142M | $1.8B |
| Net IncomeAfter-tax profit | -$145M | $1.1B |
| Free Cash FlowCash after capex | -$120M | $1.3B |
| Gross MarginGross profit ÷ Revenue | +48.8% | +78.1% |
| Operating MarginEBIT ÷ Revenue | -171.5% | +26.7% |
| Net MarginNet income ÷ Revenue | -173.0% | +17.6% |
| FCF MarginFCF ÷ Revenue | -143.3% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +62.7% | +13.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.0% | -75.4% |
EW leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
EW leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | KMTSKESTRA MEDICAL TE… | EWEdwards Lifescien… |
|---|---|---|
| Market CapShares × price | $1.3B | $47.7B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $45.5B |
| Trailing P/EPrice ÷ TTM EPS | -4.19x | 45.23x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 27.52x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.39x |
| EV / EBITDAEnterprise value multiple | — | 25.37x |
| Price / SalesMarket cap ÷ Revenue | 20.99x | 7.86x |
| Price / BookPrice ÷ Book value/share | 5.19x | 4.69x |
| Price / FCFMarket cap ÷ FCF | — | 35.75x |
EW leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
EW leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
EW delivers a 10.4% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-69 for KMTS. EW carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to KMTS's 0.22x.
| Metric | KMTSKESTRA MEDICAL TE… | EWEdwards Lifescien… |
|---|---|---|
| ROE (TTM)Return on equity | -68.8% | +10.4% |
| ROA (TTM)Return on assets | -48.8% | +8.0% |
| ROICReturn on invested capital | -6.6% | +15.5% |
| ROCEReturn on capital employed | -78.6% | +14.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.22x | 0.07x |
| Net DebtTotal debt minus cash | -$193M | -$2.2B |
| Cash & Equiv.Liquid assets | $238M | $2.9B |
| Total DebtShort + long-term debt | $44M | $705M |
| Interest CoverageEBIT ÷ Interest expense | -13.93x | — |
EW leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — KMTS and EW each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KMTS five years ago would be worth $9,853 today (with dividends reinvested), compared to $8,980 for EW. Over the past 12 months, EW leads with a +10.3% total return vs KMTS's -1.5%. The 3-year compound annual growth rate (CAGR) favors KMTS at -0.5% vs EW's -2.4% — a key indicator of consistent wealth creation.
| Metric | KMTSKESTRA MEDICAL TE… | EWEdwards Lifescien… |
|---|---|---|
| YTD ReturnYear-to-date | -11.8% | -3.0% |
| 1-Year ReturnPast 12 months | -1.5% | +10.3% |
| 3-Year ReturnCumulative with dividends | -1.5% | -7.0% |
| 5-Year ReturnCumulative with dividends | -1.5% | -10.2% |
| 10-Year ReturnCumulative with dividends | -1.5% | +133.4% |
| CAGR (3Y)Annualised 3-year return | -0.5% | -2.4% |
Evenly matched — KMTS and EW each lead in 3 of 6 comparable metrics.
Risk & Volatility
EW leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EW is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than KMTS's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EW currently trades 94.2% from its 52-week high vs KMTS's 71.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KMTSKESTRA MEDICAL TE… | EWEdwards Lifescien… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 0.65x |
| 52-Week HighHighest price in past year | $30.00 | $87.89 |
| 52-Week LowLowest price in past year | $13.25 | $72.30 |
| % of 52W HighCurrent price vs 52-week peak | +71.7% | +94.2% |
| RSI (14)Momentum oscillator 0–100 | 48.1 | 54.7 |
| Avg Volume (50D)Average daily shares traded | 357K | 4.7M |
EW leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KMTS as "Buy" and EW as "Buy". Consensus price targets imply 30.1% upside for KMTS (target: $28) vs 16.6% for EW (target: $97). KMTS is the only dividend payer here at 0.16% yield — a key consideration for income-focused portfolios.
| Metric | KMTSKESTRA MEDICAL TE… | EWEdwards Lifescien… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $28.00 | $96.53 |
| # AnalystsCovering analysts | 4 | 48 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | — |
| Dividend StreakConsecutive years of raises | 5 | — |
| Dividend / ShareAnnual DPS | $0.03 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
EW leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallEdwards Lifesciences Corpor… (EW)Leads 4 of 6 categories
Loading custom metrics...
KMTS vs EW: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is KMTS or EW a better buy right now?
For growth investors, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is the stronger pick with 115. 1% revenue growth year-over-year, versus 11. 5% for Edwards Lifesciences Corporation (EW). Edwards Lifesciences Corporation (EW) offers the better valuation at 45. 2x trailing P/E (27. 5x forward), making it the more compelling value choice. Analysts rate KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KMTS or EW?
Over the past 5 years, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) delivered a total return of -1. 5%, compared to -10. 2% for Edwards Lifesciences Corporation (EW). Over 10 years, the gap is even starker: EW returned +133. 4% versus KMTS's -1. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KMTS or EW?
By beta (market sensitivity over 5 years), Edwards Lifesciences Corporation (EW) is the lower-risk stock at 0.
65β versus KESTRA MEDICAL TECHNOLOGIES, LTD. 's 1. 87β — meaning KMTS is approximately 187% more volatile than EW relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 22% for KESTRA MEDICAL TECHNOLOGIES, LTD. — giving it more financial flexibility in a downturn.
04Which is growing faster — KMTS or EW?
By revenue growth (latest reported year), KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is pulling ahead at 115. 1% versus 11. 5% for Edwards Lifesciences Corporation (EW). On earnings-per-share growth, the picture is similar: Edwards Lifesciences Corporation grew EPS -73. 7% year-over-year, compared to -151. 5% for KESTRA MEDICAL TECHNOLOGIES, LTD.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KMTS or EW?
Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.
7% net margin versus -190. 3% for KESTRA MEDICAL TECHNOLOGIES, LTD. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus -177. 8% for KMTS. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is KMTS or EW more undervalued right now?
Analyst consensus price targets imply the most upside for KMTS: 30.
1% to $28. 00.
07Which pays a better dividend — KMTS or EW?
In this comparison, KMTS (0.
2% yield) pays a dividend. EW does not pay a meaningful dividend and should not be held primarily for income.
08Is KMTS or EW better for a retirement portfolio?
For long-horizon retirement investors, Edwards Lifesciences Corporation (EW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
65), +133. 4% 10Y return). KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EW: +133. 4%, KMTS: -1. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KMTS and EW?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KMTS is a small-cap high-growth stock; EW is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(KMTS: 62.7% · EW: 13.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.